Study wrapper · #945
Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease.
Heerspink HJL, van Raalte DH, Bjornstad P, et al. Nephrology, dialysis, transplantation. 2026.
DOI: 10.1093/ndt/gfaf230PubMed: 41160422
Editor's note
This paper reports the design and baseline characteristics of an ongoing mechanistic trial rather than any results. It establishes how retatrutide's effects on measured glomerular filtration rate and kidney structure will be evaluated, with outcomes still pending. Worth flagging as a trial to watch, with no efficacy data yet available.
Plain-language abstract
A design paper describing the rationale and baseline characteristics of the TRANSCEND-CKD Phase 2b trial, which is studying retatrutide's effects on kidney function in adults with overweight or obesity and chronic kidney disease.
Related coverage
Supported
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
BMJ (Clinical research ed.)n=——2026
Weak / none
Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats.
Behavioural brain researchn=——2026
Supported
Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
High blood pressure & cardiovascular preventionn=——2026